altprotein Group

The South Korea Mitochondrial Myopathy Diagnosis and Treatment Market is expanding as advancements in genetic testing and personalized medicine enhance the detection and management of this rare neuromuscular disorder. Mitochondrial myopathy, caused by defects in mitochondrial DNA or nuclear genes, leads to muscle weakness, exercise intolerance, and systemic complications. In South Korea, growing awareness of rare diseases, increasing availability of genetic counseling, and government-backed healthcare initiatives are driving early diagnosis and improved patient care.

Leading hospitals and diagnostic laboratories are adopting next-generation sequencing (NGS), whole-exome sequencing, and advanced biochemical tests to identify mitochondrial defects with higher precision. These technologies enable accurate differentiation of mitochondrial myopathy from other muscular disorders, facilitating timely treatment interventions. Pharmaceutical companies and research institutions are focusing on developing novel therapies, including gene therapies, enzyme replacement strategies, and mitochondrial-targeted antioxidants, to slow disease progression and enhance quality of life.

The South Korean government’s support for rare disease…

123412